Long-Term Response and Postsurgical Complete Remissions After Treatment With Sunitinib Malate, an Oral Multitargeted Receptor Tyrosine Kinase Inhibitor, in Patients With Metastatic Renal Cell Carcinoma

Author： Ayllon Jorge   Beuselinck Benoit   Morel Alexandre   Barrascout Eduardo   Medioni Jacques   Scotte Florian   Oudard Stééphane  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.29, Iss.4, 2011-04, pp. : 282-285

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib

By Rosenbaum S.  

Supportive Care in Cancer, Vol. 16, Iss. 6, 2008-06 ,pp. : 557-566

Springer Publishing Company

Access to resources Recommend Favorite

Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor

By Sabbatini Roberto   Ortega Cinizia   Procopio Giuseppe   Masini Cristina   Galligioni Enzo   Porta Camillo  

Future Oncology, Vol. 9, Iss. 6, 2013-06 ,pp. : 831-843

Future Medicine

Access to resources Recommend Favorite

Sunitinib for metastatic renal cell carcinoma

By Mukherji Deborah   Larkin James   Pickering Lisa  

Future Oncology, Vol. 6, Iss. 9, 2010-09 ,pp. : 1377-1385

Future Medicine

Access to resources Recommend Favorite

Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

By Bono Petri   Rautiola Juhana   Utriainen Tapio   Joensuu Heikki  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 569-573

Informa Healthcare

Access to resources Recommend Favorite

Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

By Yasuda Yosuke   Saito Kazutaka   Yuasa Takeshi   Kitsukawa Shinichi   Urakami Shinji   Yamamoto Shinya   Yonese Junji   Takahashi Shunji   Fukui Iwao  

International Journal of Clinical Oncology, Vol. 18, Iss. 5, 2013-10 ,pp. : 884-889

Springer Publishing Company

Access to resources Recommend Favorite